Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Rok Cerne is active.

Publication


Featured researches published by Rok Cerne.


Assay and Drug Development Technologies | 2010

Triphenylphosphine Oxide Is a Potent and Selective Inhibitor of the Transient Receptor Potential Melastatin-5 Ion Channel

R. Kyle Palmer; Karnail S. Atwal; Ivona Bakaj; Stacy Carlucci-Derbyshire; M. N. Tulu Buber; Rok Cerne; Rosa Y. Cortés; Heather Devantier; Vincent Jorgensen; Aaron Pawlyk; S. Paul Lee; Dennis Sprous; Zheng Zhang; Robert W. Bryant

Transient receptor potential melastatin-5 (TRPM5) is a calcium-gated monovalent cation channel expressed in highly specialized cells of the taste bud and gastrointestinal tract, as well as in pancreatic β-cells. Well established as a critical signaling protein for G protein-coupled receptor-mediated taste pathways, TRPM5 also has recently been implicated as a regulator of incretin and insulin secretion. To date, no inhibitors of practical use have been described that could facilitate investigation of TRPM5 functions in taste or secretion of metabolic hormones. Using recombinant TRPM5-expressing cells in a fluorescence imaging plate reader-based membrane potential assay, we identified triphenylphosphine oxide (TPPO) as a selective and potent inhibitor of TRPM5. TPPO inhibited both human (IC₅₀ = 12 μM) and murine TRPM5 (IC₅₀ = 30 μM) heterologously expressed in HEK293 cells, but had no effect (up to 100 μM) on the membrane potential responses of TRPA1, TRPV1, or TRPM4b. TPPO also inhibited a calcium-gated TRPM5-dependent conductance in taste cells isolated from the tongues of transgenic TRPM5(+/)⁻ mice. In contrast, TPP had no effect on TRPM5 responses, indicating a strict requirement of the oxygen atom for activity. Sixteen additional TPPO derivatives also inhibited TRPM5 but none more potently than TPPO. Structure-activity relationship of tested compounds was used for molecular modeling-based analysis to clarify the positive and negative structural contributions to the potency of TPPO and its derivatives. TPPO is the most potent TRPM5 inhibitor described to date and is the first demonstrated to exhibit selectivity over other channels.


Assay and Drug Development Technologies | 2010

Overexpression of human transient receptor potential M5 upregulates endogenous human transient receptor potential A1 in a stable HEK cell line.

M. N. Tulu Buber; Rok Cerne; Rosa Y. Cortés; Robert W. Bryant; Seunghun Paul Lee

Transient receptor potential M5 (TRPM5), a monovalent cation channel, is primarily activated by increases in intracellular calcium. However, we found unexpectedly that allyl isothiocyanate (AITC) and structural analogs triggered a membrane potential and calcium dye responses in TRPM5-HEK cells (AITC EC₅₀ = 9.0 ± 2.4 μM, n = 5). Although AITC and its analogs were more potent on transient receptor potential A1 (TRPA1)-HEK cells (AITC EC₅₀ = 0.23 ± 0.03 μM, n = 4), the rank order potency of these compounds were similar for TRPM5- and TRPA1-HEK cells. No response to these compounds was seen in parental HEK cells, TRPM5-CHO cells, and TRPM4b-, TRPM8-, or TRPV1-transfected HEK cells. An AITC-evoked current in TRPM5-HEK cells was confirmed in whole-cell voltage clamp recording. AITC elicited an intracellular calcium increase that was not dependent on phorpholipase C(β)₂ (PLC(β)₂) activation but was dependent on extracellular calcium concentration. TRPA1 mRNA was upregulated fourfold in TRPM5-HEK cells compared with parental cells. In contrast, TRPA1 was not upregulated in HEK cells transfected in a similar manner with TRPV1 or TRPM8 genes. The AITC response was blocked by a TRPA1 inhibitor and reduced by a TRPM5 inhibitor and by targeted TRPA1 siRNA. These results suggest that TRPM5 may play a role in upregulating endogenous expression of TRPA1, that TRPA1 activation may be an additional trigger for co-expressed calcium-dependent ion channels such as TRPM5, and that TRPM5 may amplify responses to TRPA1 ligands.


Archive | 2006

Hydrazone derivatives and uses thereof

Robert W. Bryant; Roy Kyle Palmer; Rok Cerne; Karnail S. Atwal; Seunghun Paul Lee; Anita B. Atwal


Archive | 2007

Heterocyclic compounds as sweetener enhancers

Karnail S. Atwal; Robert W. Bryant; Ivona Bakaj; Roy Kyle Palmer; Rok Cerne; Anita B. Atwal


Archive | 2008

Use of a TRPM5 Inhibitor to Regulate Insulin and GLP-1 Release

S. Paul Lee; Peihong Zhou; M. N. Tulu Buber; Rok Cerne; Robert G. Bryant; F. Raymond Salemme; Gillian Morgan


Archive | 2007

Triaryl substituted imidazole derivatives and taste-inhibiting uses thereof

Karnail S. Atwal; Anita B. Atwal; Robert W. Bryant; Seunghun Paul Lee; Roy Kyle Palmer; Rok Cerne


Archive | 2008

Modulation of the cooperativity between the ion channels trpm5 and trpa1

S. Paul Lee; Tulu Buber; Rok Cerne; Robert W. Bryant


The FASEB Journal | 2007

Thymol and related phenols are potent activators of the transient receptor potential channel, TRPA1

S. Paul Lee; M. N. Tulu Buber; Rok Cerne; Rosa Y. Cortés; Robert W. Bryant


Archive | 2008

Modulation de la capacité de coopération entre les canaux ioniques trpm5 et trpa1

S. Paul Lee; Tulu Buber; Rok Cerne; Robert W. Bryant


Archive | 2008

Mutant non-desensibilisant du canal ionique a potentiel de recepteur transitoire (trpms)

Robert W. Bryant; Seunghun Paul Lee; Rok Cerne; M. N. Tulu Buber; Ivona Bakaj; Roy Kyle Palmer

Collaboration


Dive into the Rok Cerne's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge